Share on StockTwits

Avalanche Biotechnologies (NASDAQ: AAVL) received a number of ratings updates from brokerages and research firms in the last week:

  • Avalanche Biotechnologies is now covered by analysts at Piper Jaffray. They set an “overweight” rating and a $39.00 price target on the stock.
  • Avalanche Biotechnologies is now covered by analysts at Jefferies Group. They set a “buy” rating and a $40.00 price target on the stock.
  • Avalanche Biotechnologies is now covered by analysts at William Blair. They set an “outperform” rating and a $52.00 price target on the stock.
  • Avalanche Biotechnologies is now covered by analysts at Cowen and Company. They set an “outperform” rating and a $45.00 price target on the stock.

Avalanche Biotechnologies Inc (NASDAQ:AAVL) opened at 30.24 on Wednesday. Avalanche Biotechnologies Inc has a 1-year low of $22.00 and a 1-year high of $32.375. The stock has a 50-day moving average of $27.17 and a 200-day moving average of $27.17. The company’s market cap is $645.9 million.

Avalanche Biotechnologies, Inc (NASDAQ:AAVL) is a biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases.

Receive News & Ratings for Avalanche Biotechnologies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalanche Biotechnologies Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.